Pfizer Company Profile
✉ Email this page to a colleague
What is the competitive landscape for PFIZER, and what generic alternatives to PFIZER drugs are available?
PFIZER has one hundred and ninety-four approved drugs.
There are forty-seven US patents protecting PFIZER drugs. There is one tentative approval on PFIZER drugs.
There are one thousand and seventeen patent family members on PFIZER drugs in seventy countries and two hundred and fifty-eight supplementary protection certificates in nineteen countries.
Summary for Pfizer
International Patents: | 1017 |
US Patents: | 47 |
Tradenames: | 159 |
Ingredients: | 130 |
NDAs: | 194 |
Drug Master File Entries: | 3 |
Patent Litigation for Pfizer: | See patent lawsuits for Pfizer |
PTAB Cases with Pfizer as petitioner: | See PTAB cases with Pfizer as petitioner |
Drugs and US Patents for Pfizer
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pfizer | COLESTID | colestipol hydrochloride | TABLET;ORAL | 020222-001 | Jul 19, 1994 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Pfizer | TESSALON | benzonatate | CAPSULE;ORAL | 011210-001 | Approved Prior to Jan 1, 1982 | AA | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Pfizer | TETRACYN | tetracycline hydrochloride | INJECTABLE;INJECTION | 060096-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Pfizer | GLYNASE | glyburide | TABLET;ORAL | 020051-003 | Sep 24, 1993 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Pfizer | MINIPRESS | prazosin hydrochloride | CAPSULE;ORAL | 017442-003 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Pfizer
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Pfizer Pharms | REZULIN | troglitazone | TABLET;ORAL | 020720-003 | Aug 4, 1997 | 5,478,852 | ⤷ Try a Trial |
Pfizer Pharms | ACCUPRIL | quinapril hydrochloride | TABLET;ORAL | 019885-002 | Nov 19, 1991 | 5,684,016*PED | ⤷ Try a Trial |
Pfizer | COVERA-HS | verapamil hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020552-002 | Feb 26, 1996 | 5,141,752 | ⤷ Try a Trial |
Pfizer | MINIPRESS XL | prazosin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 019775-001 | Jan 29, 1992 | 4,765,989 | ⤷ Try a Trial |
Pfizer Pharms | ACCURETIC | hydrochlorothiazide; quinapril hydrochloride | TABLET;ORAL | 020125-001 | Dec 28, 1999 | 4,743,450*PED | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for PFIZER drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Capsules | 5 mg and 10 mg | ➤ Subscribe | 2005-06-21 |
➤ Subscribe | For Injection | 500 mg/vial | ➤ Subscribe | 2011-06-17 |
➤ Subscribe | Oral Suspension | 100 mg/5 mL | ➤ Subscribe | 2009-08-03 |
➤ Subscribe | Injection | 2 mg/mL, 100 mL bag | ➤ Subscribe | 2009-12-29 |
➤ Subscribe | Tablets | 5 mg | ➤ Subscribe | 2016-11-07 |
➤ Subscribe | Delayed-release Tablets | 50 mg/0.2 mg | ➤ Subscribe | 2009-06-29 |
➤ Subscribe | Extended-release Tablets | 11 mg | ➤ Subscribe | 2016-11-07 |
➤ Subscribe | Capsules | 20 mg, 40 mg, 60 mg and 80 mg | ➤ Subscribe | 2005-02-07 |
➤ Subscribe | Capsules | 75 mg, 100 mg and 125 mg | ➤ Subscribe | 2019-02-04 |
➤ Subscribe | Capsules | 0.125 mg, 0.25 mg, and 0.5 mg | ➤ Subscribe | 2014-05-01 |
➤ Subscribe | Tablets | 600 mg | ➤ Subscribe | 2005-12-21 |
➤ Subscribe | Injection | 2 mg/mL, 300 mL bag | ➤ Subscribe | 2009-09-01 |
➤ Subscribe | Tablets | 1 g | ➤ Subscribe | 2005-08-23 |
➤ Subscribe | Delayed-release Tablets | 75 mg/0.2 mg | ➤ Subscribe | 2008-11-28 |
➤ Subscribe | Extended-release Tablets | 4 mg and 8 mg | ➤ Subscribe | 2012-10-31 |
➤ Subscribe | Injection | 20 mg/mL, 2 mL and 5 mL vials | ➤ Subscribe | 2004-07-26 |
International Patents for Pfizer Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
South Korea | 20180080343 | ⤷ Try a Trial |
Australia | 2005239878 | ⤷ Try a Trial |
Slovenia | 2326621 | ⤷ Try a Trial |
Cyprus | 1120734 | ⤷ Try a Trial |
Denmark | 3286176 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Pfizer Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1470124 | 1790011-9 | Sweden | ⤷ Try a Trial | PRODUCT NAME: PALBOCICLIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REG. NO/DATE: EU/1/16/1147 20161111 |
2958921 | CA 2022 00003 | Denmark | ⤷ Try a Trial | PRODUCT NAME: ABROCITINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/21/1593 20211210 |
0328535 | 96C0021 | Belgium | ⤷ Try a Trial | PRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209 |
2170860 | 20C1038 | France | ⤷ Try a Trial | PRODUCT NAME: GLASDEGIB, OPTIONELLEMENT SOUS LA FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, NOTAMMENT LE SEL DE MALEATE; REGISTRATION NO/DATE: EU/1/20/1451 20200629 |
1470124 | CA 2017 00010 | Denmark | ⤷ Try a Trial | PRODUCT NAME: PALBOCICLIB, EVENTUELT I FORM AF EN FARMACEUTISK ACCEPTABEL ESTER ELLER ET FARMACEUTISK ACCEPTABELT SALT, AMID ELLER PRODRUG; REG. NO/DATE: EU/1/16/1147/001-006 20161111 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.